American Society of Hematology (ASH) 2012 Converage

ASH 2012

ASH: Molecular Response Predicts Long-Term Outcomes in CP-CML

In patients with newly diagnosed chronic phase chronic myeloid leukemia treated with bosutinib, an early Bcr-Abl/Abl ratio of ≤10% was associated with higher rates of major molecular response and complete cytogenetic response, according to data presented at the 54th American Society of Hematology Annual Meeting and Exposition.

Next post in ASH 2012